Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Bank, banking, berubicinol, Bulletin, Carlo, clearing, codified, consummation, contacted, CRO, Deposit, deter, disposition, DSMB, effectuate, exceeding, exposure, fundamental, hurdle, ID, illustrating, insolvent, inventory, matter, Monte, owed, pertain, Pomeranian, predefined, properly, PU, PUM, PUs, Quantifying, rata, receivership, refinancing, refundable, retroactively, SAB, Silicon, simulation, Szczecin, tail, threatened, unaudited, unexercised, Valley, Wainright, wrote
Filing tables
Filing exhibits
CNSP similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements on Forms S-3 (File Nos. 333-262262 and 333-252471), Form S-8 (File No. 333-239998), and Forms S-1 (File Nos. 333-249068, 333-267975 and 333-251530) of our report dated March 31, 2023 with respect to the audited financial statements of CNS Pharmaceuticals, Inc. (the “Company”) appearing in this Annual Report on Form 10-K of the Company for the year ended December 31, 2022. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
/s/ MaloneBailey, LLP
www.malonebailey.com
Houston, Texas
March 31, 2023